News & Events about Y Mabs Therapeutics Inc.
Did you lose money on investments in Y-mAbs Therapeutics? If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contactJoseph R. Seidman, Jr. at (877) 779-1414orseidman@bernlieb.com to discuss your rights. NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB PR Newswire NEW YORK, Feb. 6, 2023 NEW YORK, Feb. 6, 2023...
BENSALEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ...
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and Invivyd, ...
LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingMarch 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (Y-mAbs or the ...